Sustained release compositions and a method of preparing pharmaceutical compositions
US6143328A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Mar 8, 1999 |
| Grant date | Nov 7, 2000 |
| Priority date | — |
| Expiry date | Mar 8, 2019 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K31/135
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Sustained release pharmaceutical formulations containing morphine, or a pharmaceutically acceptable salt thereof, as active ingredient, suitable for administration on a once daily basis, are disclosed. In a first aspect, an orally administrable sustained release unit dosage form gives a peak plasma level at 1.0 to 6 hours after administration. In a second aspect, the formulation provides a W.sub.50 for the M-6-G metabolite for morphine of between 4 and 12 hours. A third aspect concerns the pharmaceutical unit dosage form obtained by compressing multiparticulates comprising a pharmaceutically active substance in a matrix of hydrophobic fusible material having a melting point of from 35 to 150.degree. C.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.